Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Plans New Fees For IVD Prequalification In Early 2018

Executive Summary

A new fee structure for the prequalification of in vitro diagnostics by the World Health Organization is expected to come into effect in early 2018 following the introduction of a fee-for-service framework for medicines and vaccines in January 2017.

You may also be interested in...



New WHO Prequalification Fees To Reap $20m A Year; Prices Could Rise As A Result

A new financing arrangement due to take effect in January 2017 will see manufacturers paying fees for the World Health Organization’s prequalification program in an effort to give it a firmer footing in the long term. While manufacturers have welcomed the new fee structure, the NGO Health Action International says safeguards will be needed to ensure regulation remains robust.

WHO Pilots Faster Pre-Qualification Procedure For IVDs

Diagnostics are assessed by the World Health Organization to support use for priority diseases in low-resource regions. Under a new WHO process, performance evaluations for IVDs may be initiated at a much earlier stage than is currently allowed.

Report Changes To WHO Prequalified IVDs Or Get Dropped From List, Guidance Says

The World Health Organization has issued draft guidance on what changes relating to IVDs that fall under its prequalification program manufacturers must report to the WHO, what changes do not need reporting, and what changes might require a new application for prequalification1.

Topics

UsernamePublicRestriction

Register

MT103911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel